Characterization of the anti-angiogenic properties of arresten, an α1β1 integrin-dependent collagen-derived tumor suppressor

Experimental Cell Research

Volumn 314, Issue 18, 2008, Pages 3292-3305

  Nyberg, Pia ^a,b   Xie, Liang ^a   Sugimoto, Hikaru ^a   Colorado, Pablo ^a   Sund, Malin ^a   Holthaus, Kathryn ^a   Sudhakar, Akulapalli ^a   Salo, Tuula ^b,c   Kalluri, Raghu ^a,d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Angiogenesis; Apoptosis; Arresten; Basement membrane; Collagen IV; Integrin

Indexed keywords

ANGIOGENESIS INHIBITOR; ARRESTEN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; PRIORITY JOURNAL; TUMOR GROWTH;

MUS;

EID: 54149116062     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.08.011     Document Type: Article

References (45)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
2. Folkman J. Angiogenesis and apoptosis. Semin. Cancer Biol. 13 (2003) 159-167
3. Madri J.A. Extracellular matrix modulation of vascular cell behaviour. Transpl. Immunol. 5 (1997) 179-183
4. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit. Rev. Biochem. Mol. Biol. 27 (1992) 93-127
5. Prockop D.J., and Kivirikko K.I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. (1995) 64403-64434
6. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
7. Maeshima Y., Colorado P.C., Torre A., Holthaus K.A., Grunkemeyer J.A., Ericksen M.B., Hopfer H., Xiao Y., Stillman I.E., and Kalluri R. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275 (2000) 21340-21348
8. Kamphaus G.D., Colorado P.C., Panka D.J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J.W., Sukhatme V.P., and Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275 (2000) 1209-1215
9. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K., Ericksen M.B., Dhanabal M., Simons M., Post M., Kufe D.W., Weichselbaum R.R., Sukhatme V.P., and Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60 (2000) 2520-2526
10. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., and Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4766-4771
11. Sudhakar A., Nyberg P., Keshamouni V.G., Mannam A.P., Li J., Sugimoto H., Cosgrove D., and Kalluri R. Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. J. Clin. Invest. 115 (2005) 2801-2810
12. Plow E.F., Haas T.A., Zhang L., Loftus J., and Smith J.W. Ligand binding to integrins. J. Biol. Chem. 275 (2000) 21785-21788
13. Pozzi A., Wary K.K., Giancotti F.G., and Gardner H.A. Integrin alpha1beta1 mediates a unique collagen-dependent proliferation pathway in vivo. J. Cell. Biol. 142 (1998) 587-594
14. Defilippi P., van Hinsbergh V., Bertolotto A., Rossino P., Silengo L., and Tarone G. Differential distribution and modulation of expression of alpha 1/beta 1 integrin on human endothelial cells. J. Cell. Biol. 114 (1991) 855-863
15. Liu S., Tobias R., McClure S., Styba G., Shi Q., and Jackowski G. Removal of endotoxin from recombinant protein preparations. Clin. Biochem. 30 (1997) 455-463
16. Maeshima Y., Yerramalla U.L., Dhanabal M., Holthaus K.A., Barbashov S., Kharbanda S., Reimer C., Manfredi M., Dickerson W.M., and Kalluri R. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol. Chem. 276 (2001) 31959-31968
17. Salo T., Lyons J.G., Rahemtulla F., Birkedal-Hansen H., and Larjava H. Transforming growth factor-beta1 up-regulates type IV collagenase expression in cultured human keratinocytes. J. Biol. Chem. 266 (1991) 11436-11441
18. Nyberg P., Heikkila P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U.H., Pihlajaniemi T., and Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation on matrix metalloprotease-2, -9, and -13. J. Biol. Chem. 278 (2003) 22404-22411
19. Gardner H., Kreidberg J., Koteliansky V., and Jaenisch R. Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev. Biol. 175 (1996) 301-313
20. Pozzi A., LeVine W.F., and Gardner H.A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21 (2002) 272-281
21. Tedjarati S., Baker C.H., Apte S., Huang S., Wolf J.K., Killion J.J., and Fidler I.J. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin. Cancer Res. 8 (2002) 2413-2422
22. Senger D.R., Claffey K.P., Benes J.E., Perruzzi C.A., Sergiou A.P., and Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13612-13617
23. Mendrick D.L., Kelly D.M., duMont S.S., and Sandstrom D.J. Glomerular epithelial and mesangial cells differentially modulate the binding specificities of VLA-1 and VLA-2. Lab. Invest. 72 (1995) 367-375
24. Xiang R., Lode H.N., Dreier T., Gillies S.D., and Reisfeld R.A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res. 58 (1998) 3918-3925
25. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., Hynes R.O., Werb Z., Sudhakar A., and Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3 (2003) 589-601
26. Cory S., Huang D.C., and Adams J.M. The Bcl-family: roles in cell survival and oncogenesis. Oncogene 22 (2003) 8590-8607
27. Maeshima Y., Colorado P.C., and Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275 (2000) 23745-23750
28. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., Pauly R.R., Grant D.S., and Martin G.R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67 (1992) 519-528
29. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., and Gardner H.A. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2202-2207
30. Mundel T.M., and Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc. Res. 74 (2007) 85-89
31. Panka D.J., and Mier J.W. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J. Biol. Chem. 278 (2003) 37632-37636
32. He G.A., Luo J.X., Zhang T.Y., Wang F.Y., and Li R.F. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem. Biophys. Res. Commun. 312 (2003) 801-805
33. He G.A., Luo J.X., Zhang T.Y., Hu Z.S., and Wang F.Y. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. Biochem. Biophys. Res. Commun. 318 (2004) 354-360
34. Shahan T.A., Ziaie Z., Pasco S., Fawzi A., Bellon G., Monboisse J.C., and Kefalides N.A. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res. 59 (1999) 4584-4590
35. Segev A., Nili N., and Strauss B.H. The role of perlecan in arterial injury and angiogenesis. Cardiovasc. Res. 63 (2004) 603-610
36. Bix G., Fu J., Gonzalez E.M., Macro L., Barker A., Campbell S., Zutter M.M., Santoro S.A., Kim J.K., Hook M., Reed C.C., and Iozzo R.V. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J. Cell. Biol. 166 (2004) 97-109
37. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., Pihlajaniemi T., Alitalo K., and Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1024-1029
38. Karumanchi S.A., Jha V., Ramchandran R., Karihaloo A., Tsiokas L., Chan B., Dhanabal M., Hanai J.I., Venkataraman G., Shriver Z., Keiser N., Kalluri R., Zeng H., Mukhopadhyay D., Chen R.L., Lander A.D., Hagihara K., Yamaguchi Y., Sasisekharan R., Cantley L., and Sukhatme V.P. Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell 7 (2001) 811-822
39. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3 (2003) 422-433
40. Knight C.G., Morton L.F., Onley D.J., Peachey A.R., Messent A.J., Smethurst P.A., Tuckwell D.S., Farndale R.W., and Barnes M.J. Identification in collagen type I of an integrin alpha2 beta1-binding site containing an essential GER sequence. J. Biol. Chem. 273 (1998) 33287-33294
41. Knight C.G., Morton L.F., Peachey A.R., Tuckwell D.S., Farndale R.W., and Barnes M.J. The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J. Biol. Chem. 275 (2000) 35-40
42. Renner C., Sacca B., and Moroder L. Synthetic heterotrimeric collagen peptides as mimics of cell adhesion sites of the basement membrane. Biopolymers 76 (2004) 34-47
43. Xu J., Rodriguez D., Peticlerc E., Kim J.J., Hangai M., Moon Y.S., Davis G.E., and Brooks P.C. Proteolytic exposure of cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154 (2001) 1069-1079
44. Petitclerc E., Boutaud A., Prestayko A., Xu J., Sado Y., Ninomiya Y., Sarras Jr. M.P., Hudson B.G., and Brooks P.C. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 275 (2000) 8051-8061
45. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2 (2002) 727-739